The work of developing vaccines to protect children in the corona epidemic is continuously going on. The Director General of India has now given permission to Serum Institute to conduct vaccine trials for children aged 7 to 11 years. The Serum Institute of India (SII) on Tuesday got the nod for the Phase II and III clinical trials of US biotechnology firm Novavax’s Indian variant ‘Kovovax’. This is the third COVID-19 vaccine to be tested in children in India after Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCoV-D.
The subject matter expert committee (SEC) of India’s Central Drugs Standard Control Organization recommended that the company be allowed to test the vaccine in children aged seven to 11 years. A person familiar with the matter spoke on the condition of anonymity But said, “Kovovax has been approved. The company can go ahead and recruit volunteers as per the prescribed protocol.”
If schools open all over India, then it is necessary that the vaccine is available for the children. At present, only people 18 years of age and above are allowed to get the vaccine in India.
In July, the Serum Institute got permission to conduct clinical trials on children aged 12 to 17 years. These trials are going on. Kovovax could be launched in October, SII Chief Executive Officer Adar Poonawalla said after a meeting with Home Minister Amit Shah last month.